Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Longeveron ( (LGVN) ) has provided an update.
On February 9, 2026, interim CEO Than Powell resigned from his temporary role at Longeveron but remained with the company in business development, as the board appointed veteran biotech executive Stephen H. Willard as permanent CEO effective February 11, 2026. Longeveron tied Willard’s compensation to a mix of cash and equity, including substantial stock and option grants, while simultaneously imposing a temporary 50% pay cut on its CEO and executive chairman and rolling out broader cost-cutting measures such as employee furloughs and reduced board fees to conserve cash ahead of pivotal clinical trial milestones.
The leadership change comes as Longeveron sharpens its corporate focus on delivering top-line data from its pivotal Phase 2b trial of laromestrocel in hypoplastic left heart syndrome expected in the third quarter of 2026, which the FDA has indicated could support a future biologics license application if successful. The combination of a seasoned fundraiser at the helm, equity-heavy executive packages and aggressive cost-containment efforts underscores the company’s drive to extend its capital runway and strengthen its position in the competitive regenerative medicine space at a critical juncture for its lead asset.
The most recent analyst rating on (LGVN) stock is a Hold with a $0.53 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.
Spark’s Take on LGVN Stock
According to Spark, TipRanks’ AI Analyst, LGVN is a Underperform.
Longeveron’s overall stock score is heavily impacted by its poor financial performance and valuation metrics. The technical analysis also indicates bearish momentum. While there are some positive developments in clinical trials and corporate governance, these are overshadowed by financial instability and the risk of Nasdaq delisting.
To see Spark’s full report on LGVN stock, click here.
More about Longeveron
Longeveron Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing cellular therapies for life-threatening rare pediatric diseases and chronic aging-related conditions. Its lead investigational product, laromestrocel (LOMECEL-B), an allogeneic mesenchymal stem cell therapy, targets indications including hypoplastic left heart syndrome, Alzheimer’s disease and pediatric dilated cardiomyopathy.
Average Trading Volume: 311,608
Technical Sentiment Signal: Sell
Current Market Cap: $11.55M
For a thorough assessment of LGVN stock, go to TipRanks’ Stock Analysis page.